ImmunityBio Mobilizes 85-Person Team for EU Anktiva Launch, Eyes Saudi Market
ImmunityBio gained EU clearance for Anktiva with BCG in non-muscle invasive bladder cancer and signed a deal with Accord Healthcare to deploy an 85-person sales team across 30 European countries. It also partnered with Biopharma and Cigalah to launch Anktiva in Saudi Arabia for bladder and lung cancer.
1. EU Regulatory Approval
The European Commission approved Anktiva used with BCG for non-muscle invasive bladder cancer, authorizing its use in carcinoma in situ with or without papillary disease.
2. Distribution Partnership and Infrastructure
ImmunityBio formed a distribution pact with Accord Healthcare, establishing an Irish subsidiary and deploying over 100 sales, medical and marketing staff—including an 85-person sales team—to commercialize Anktiva across 30 EU and EFTA countries.
3. Saudi Arabia Market Entry
The company partnered with Biopharma and Cigalah to launch Anktiva for bladder and lung cancer patients in Saudi Arabia, marking its first entry into the Gulf region.